Vorinostat
Non-Small-Cell Lung Carcinoma
H. Lee Moffitt Cancer Center and Research InstituteSmall moleculePhase 2/3Active
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 59/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Non-Small-Cell Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MOTEXAFIN GADOLINIUM HYDRATE Pharmacyclics LLC. | Phase 3 | BB |
Epoetin Alfa Ontario Clinical Oncology Group (OCOG) | Phase 3 | B |
Pelitinib | Phase 2 | B |
Enzastaurin Eli Lilly and Company | Phase 2 | B |
GADOPENTETATE University of Cologne | Phase 2 | B |
View all 13 →
Same molecule, other indications
Vorinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →